Differences

This shows you the differences between two versions of the page.

--- documentation:oncology:meeting_notes_2017_oct-19 [2017/10/28 18:02] – created rimma_belenkaya
+++ documentation:oncology:meeting_notes_2017_oct-19 [2017/10/30 15:17] (current) – rimma_belenkaya
@@ Line 1: / Line 1: @@
 {{:documentation:oncology:f-t-f_oncology_meeting.docx|Face-to-Face Oncology Meeting Notes}}
+**Next steps**
+**I. Tasks to generate the minimal viable product**
+.	Diagnosis
+a.	Vocabulary Mapping
+  * Rely only on pre-coordination of SNOMED morphology and anatomy corresponding to ICD-O histology and topography. If a pre-coordinated SNOMED diagnosis does not exist, create OMOP-generated one.
+  * Present proposal for pre-coordinated terms to SNOMED.
+b.	Diagnosis identification and verification
+  * Sourced from cancer registry based on ICDO-O – >SNOMED mapping
+  * Sourced from EMR based on ICD-9/10 -> SNOMED mapping or ICDO-O – >ICD-9/10 -> SNOMED
+  * Compare the diagnoses and patient identified from the two sources
+  * Explore how ICD-9/10 diagnosis changes in EMR, if at all, through the course of the disease
+c.	Cancer diagnosis representation in OMOP CDM – possible extension to represent recurrences
+.	Staging
+Choose vocabulary
+???
+.	Treatments
+a.	Drugs
+  * Compare SEER drugs list with RxNorm cancer drug classes and decide which one should be used in the vocabulary. If SEER is more suitable, add SEER classification to the vocabulary.
+  * Add SEER drug cocktails to the vocabulary (only ingredients, no other specifics) in EMR based on those combinations.
+  * Identify chemo regimens in EMR using SEER cocktails and validate with chemo orders when available
+  * Work on cancer Drug Era algorithm and modeling in CDM
+b.	Overlay cancer registry treatment schema (first occurrence only) with EMR details to construct complete treatment regimen
+c.	Model representation of the treatment regimen (era) in the CDM
+**II. Exploratory**
+  - Discuss with IMO procedure mappings to SNOMED and classification of cancer cases.
+  - Explore commercial solutions that claim to identify cancer treatment regimens, recurrences, progression and compare the outcomes with our attempts to identify treatment regimens
+  - Invite Andrew Stewart and Mark Denise to present their efforts and results in mapping to CDM and additional modeling
+  - Find a geneticist and oncologist to identify cancer-relevant genomic areas
+  - Find  out if we can get cancer registry data from any of the “SEER” states
+**III. Operational**
+Document challenges related to extending OHDSI infrastructure to support cancer research for NCI